Vanadate-induced cell death is dissociated from H2O2 generation

Cell Biology and Toxicology

Volumn 23, Issue 6, 2007, Pages 413-420

  Capella, M A M ^a   Capella, L S ^a   Valente, R C ^a   Gefe M ^a   Lopes, A G ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Erythroleukemic cells; Hydrogen peroxide; Renal cells; Vanadate

Indexed keywords

HYDROGEN PEROXIDE; PEROXOVANADIUM; UNCLASSIFIED DRUG; VANADIC ACID; VANADIUM DERIVATIVE;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CELL DEATH; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION; EMBRYO; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANIMALS; CELL DEATH; DOGS; FLUORESCENCE; HAPLORHINI; HUMANS; HYDROGEN PEROXIDE; K562 CELLS; OXIDATION-REDUCTION; RHODAMINES; VANADATES;

EID: 37749035195     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-007-9003-4     Document Type: Article

References (53)

1. Aureliano M, Gandara RM. Decavanadate effects in biological systems. J Inorg Biochem 2005;99:979-85.
2. Aureliano M, Joaquim N, Sousa A, Martins H, Coucelo JM. Oxidative stress in toadfish (Halobactrachus didactylus) cardiac muscle. Acute exposure to vanadate oligomers. J Inorg Biochem 2002;90:159-65.
3. Aureliano M, Tiago T, Gandara RM, et al. Interactions of vanadium(V)-citrate complexes with the sarcoplasmic reticulum calcium pump. J Inorg Biochem 2005;99:2355-61.
4. Barceloux DG. Vanadium. Toxicol Clin Toxicol 1999;37:265-78.
5. Bay BH, Sit KH, Paramanantham R, Chan YG. Hydroxyl free radicals generated by vanadyl[IV] induce cell blebbing in mitotic human Chang liver cells. BioMetals 1997;10:119-22.
6. Bevan AP, Drake PG, Yale JF, Shaver A, Posner BI. Peroxovanadium compounds: biological actions and mechanism of insulin-mimetics. Mol Cell Biochem 1995;153:49-58.
7. Boscolo P, Carmignani M, Volpe AR, et al. Renal toxicity and arterial hypertension in rats chronically exposed to vanadate. Occup Environ Med 1994;51:500-3.
8. Bruech M, Quintanilla ME, Legrum W, Koch J, Netter KJ, Fuhrmann GF. Effects of vanadate on intracellular reduction equivalents in mouse liver and the fate of vanadium in plasma, erythrocytes and liver. Toxicology 1984;31:283-95.
9. Bursztyn M, Mekler J. Acute hypertensive response to saline induced by vanadate, an insulinomimetic agent. J Hypertens 1993;11:605-9.
10. Cantley LC Jr, Aisen P. The fate of cytoplasmic vanadium. Biol Chem 1979;254:1781-4.
11. Cantley LC Jr, Josephson L, Warner R, Yanagisawa M, Lechene C, Guidotti G. Vanadate is a potent (Na, K) -ATPase inhibitor found in ATP derived from muscle. J Biol Chem 1977;252:7421-3.
12. Capella MAM, Orind M, Morales MM, Rumjanek VM, Lopes AG. Expression of functionally P-glycoprotein in MA104 kidney cells. Z Naturforsch 1999;54c:119-27.
13. Capella LS, Alcantara JSM, Moura-Neto V, Lopes AG, Capella MAM. Vanadate is toxic to adherent- growing multidrug-resistant cells. Tumor Biol 2000;21:54-62.
14. Capella LS, Gefe MR, Silva EF, et al. Reduced glutathione protect cells from ouabain toxicity. Biochim Biophys Acta 2001;1526:293-300.
15. Capella LS, Gefe MR, Silva EF, et al. Mechanisms of vanadate-induced cellular toxicity: role of cellular glutathione and NADPH. Arch Biochem Biophys 2002;406:65-72.
16. Carmignani M, Volpe AR, Boscolo P, Ripanti G, Giuliano G. Vanadate and cardiovascular system. Ital Med Lav 1995;17:51-9.
17. Cohen MD, Klein CB, Costa M. Forward mutations and DNA-protein crosslinks induced by ammonium metavanadate in cultured mammalian cells. Mutat Res 1992;269:141-8.
18. Crans DC, Smee JJ, Gaidamauskas E, Yang L. The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. Chem Rev 2004;104:849-902.
19. Ding M, Li J-J, Leonard SS, Ye J-P, et al. Vanadate-induced activation of activator protein-1: role of reactive oxygen species. Carcinogenesis 1999;20:663-8.
20. Elberg G, Li J, Schechter Y. Vanadium activates or inhibits receptor and non-receptor tyrosine kinases in cell-free experiments, depending on its oxidation state. Possible role of endogenous vanadium in controlling cellular protein kinase activity. J Biol Chem 1994;269:9521-7.
21. Evangelou AM. Vanadium in cancer treatment. Crit Rev Oncol Hematol 2002;42:249-65.
22. Fantus IG, Kadota S, Deragon G, Foster B, Posner B. Pervanadate [peroxide(s) of vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. Biochemistry 1989;28:8864-71.
23. Goh LB, Spears KJ, Yao D, et al. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 2002;64: 1569-78.
24. Gordon JA. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol 1991;201:477-82.
25. Gresser MJ, Tracey AS. Vanadate as phosphate analogs in biochemistry. In: Chasteen ND, editor. Vanadium in biological systems. Dordrecht: Kluwer; 1990. p. 63-79.
26. Huang C, Zhang Z, Ding M, et al. Vanadate induces p53 transactivation through hydrogen peroxide and causes apoptosis. J Biol Chem 2000;275:32516-22.
27. Huyer G, Liu S, Kelly J, et al. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem 1997;272:843-51.
28. Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, Koren G. Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am J Physiol 1999;277:F84-96.
29. Josephson L, Cantley LC. Isolation of a potent (Na-K)ATPase inhibitor from striated muscle. Biochemistry 1977;16:4572-8.
30. Kresja CM, Nadler SG, Esselstyn JM, Kavanagh JT, Ledbetter JA, Scieven GL. Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors. J Biol Chem 1997;272:11541-9.
31. Léonard A, Gerber GB. Mutagenicity, carcinogenicity and teratogenicity of vanadium compounds. Mutat Res 1994;317:81-8.
32. Liochev SI, Fridovich I. Superoxide generated by glutathione reductase initiates a vanadate-dependent free radical chain oxidation of NADH. Arch Biochem Biophys 1992;294:403-6.
33. Lobert S, Isern N, Hennington BS, Correia JJ. Interaction of tubulin and microtubule proteins with vanadate oligomers. Biochemistry 1994;33:6244-52.
34. Morinville A, Maysinger D, Shaver A. From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signaling. TIPS 1998;19:452-60.
35. Mukherjee B, Patra B, Mahapatra S, Banerjee P, Tiwari A, Chatterjee M. Vanadium-an element of atypical biological significance. Toxicol Lett 2004;150:135-43.
36. Nechay BR, Nanninga JB, Nechay PSE, et al. Role of vanadium in biology. Fed Proc 1986;45:123-32.
37. Ramos S, Manuel M, Tiago T, et al. Decavanadate interactions with actin: inhibition of G-actin polymerization and stabilization of decameric vanadate. J Inorg Biochem 2006;100:1734-43.
38. Rumjanek VM, Trindade GS, Wagner-Souza K, et al. Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cienc 2001;73:57-69.
39. Schechter Y, Karlish SJD. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature 1980;284:556-8.
40. Schechter Y, Goldwaser I, Mironchik M, Fridkin M, Gefel D. Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes. Coord Chem Rev 2003;237:3-11.
41. Scior T, Guevara-García A, Bernard P, Do QT, Domeyer D, Laufer S. Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review. Mini-Reviews Med Chem 2005;5:1-12.
42. Secrist JP, Burns LA, Karnitz L, Koretzky GA, Abraham RT. Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events. J Biol Chem 1993;268:5886-93.
43. Shi X, Dalal NS. Flavoenzymes reduce vanadium(V) and molecular oxygen and generate hydroxyl radical. Arch Biochem Biophys 1991;289:355-61.
44. Shi X, Dalal NS. Vanadate-mediated hydroxyl radical generation from superoxide radical in the presence of NADH: Haber-Weiss vs Fenton mechanism. Arch Biochem Biophys 1993;307:336-41.
45. Stern A, Yin X, Tsang SS, Davidson A, Moon J. Vanadium as a modulator of cellular regulatory cascades and oncogene expression. Biochem Cell Biol 1993;71:103-12.
46. Thompson KH, Orvig C. Vanadium in diabetes: 100 years from phase 0 to phase I. J Inorg Biochem 2006;100:1925-35.
47. Tiago T, Aureliano M, Gutierrez-Merino C. Decavanadate binding to a high affinity site near the myosin catalytic centre inhibits F-actin- stimulated myosin ATPase activity. Biochemistry 2004;43:5551-61.
48. Torres M, Forman HJ. Vanadate inhibition of protein tyrosine phosphatases mimics hydrogen peroxide in the activation of the ERK pathway in alveolar macrophages. Ann NY Acad Sci 2002;973:345-8.
49. Trudel S, Pâquet MR, Grinstein S. Mechanism of vanadate-induced activation of tyrosine phosphorylation and of the respiratory burst in HL60 cells. Role of reduced oxygen metabolites. Biochem J 1991;276:611-9.
50. Volberg T, Zick Y, Dror R, et al. The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J 1992;11:1733-42.
51. Ye J, Ding M, Leonard SS, et al. Vanadate induces apoptosis in epidermal JB6 P+ cells via hydrogen peroxide-mediated reactions. Mol Cell Biochem 1999;202:9-17.
52. Yin X, Davidson AJ, Tsang SS. Vanadate-induced gene expression in mouse C127 cells: roles of oxygen derived active species. Mol Cell Biochem 1992;115:85-96.
53. 2 and vanadate concomitantly stimulates protein tyrosine phosphorylation and polyphosphoinositide breakdown in different cell lines. Biochemistry 1990;29:10240-5.